
|Articles|November 13, 2012
Celgene Stock Soars on Promising Pancreatic Cancer Drug Data
Advertisement
Celgene, which unexpectedly reported the results late on Friday, did not give details of the extent of the improvement, saying it would do so at a medical meeting in January.
Abraxane is already approved to treat breast and lung cancer and the company will apply for approval from regulators to market the drug to treat pancreatic cancer as well.
Read the full story:
Source: Reuters
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept Deidentified Real-World Evidence for Select Medical Device Applications
2
ACA Subsidy Expiration Raises Concerns for Behavioral Health Access and ED Strain
3
FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Metastatic HER2-Positive Breast Cancer
4
HIV in 2025 Defined by Challenges Throughout the Year, Despite Some Advances
5








































